The company
Olema Pharmaceuticals, Inc.
OLMA · Nasdaq
OLMA stood above a rising 150-day average in 20 of the last 52 weekly readings, and has been out of that trend for the last 32 weeks. It is 44.9% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 32
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $32.4M
- Officials’ trades on record
- 0
- Institutions holding
- 180 (-7)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 20 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Cyrus HarmonDirector | sold | 12,500at $11.71 | 24 Jul 2026filed 27 Jul 2026 |
| Cyrus HarmonDirector | sold | 12,500at $11.58 | 23 Jul 2026filed 27 Jul 2026 |
| Shawnte MitchellCHIEF LEGAL OFFICER | sold | 24,767at $24.25 | 4 Mar 2026filed 5 Mar 2026 |
| Shawnte MitchellCHIEF LEGAL OFFICER | sold | 233at $24.69 | 4 Mar 2026filed 5 Mar 2026 |
| Shawnte MitchellCHIEF LEGAL OFFICER | sold | 15,000at $23.01 | 3 Mar 2026filed 5 Mar 2026 |
| Cyrus HarmonDirector | sold | 10,000at $26.88 | 20 Jan 2026filed 21 Jan 2026 |
| Shane William Charles KovacsCH. OPERATING & FINANCIAL OFF. | sold | 100,000at $28.73 | 15 Jan 2026filed 15 Jan 2026 |
| David C. MylesCH. DISCOV. & NON-CLIN DEV OFF | sold | 14,997at $28.60 | 14 Jan 2026filed 14 Jan 2026 |
| David C. MylesCH. DISCOV. & NON-CLIN DEV OFF | sold | 35,003at $28.99 | 14 Jan 2026filed 14 Jan 2026 |
| Cyrus HarmonDirector | sold | 3,489at $29.12 | 14 Jan 2026filed 16 Jan 2026 |
| Shane William Charles KovacsCH. OPERATING & FINANCIAL OFF. | sold | 3,822at $28.01 | 13 Jan 2026filed 15 Jan 2026 |
| David C. MylesCH. DISCOV. & NON-CLIN DEV OFF | sold | 49,800at $27.60 | 13 Jan 2026filed 14 Jan 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| FMR LLCadded · filed 13 Aug 2026 | 12,143,062$151.9M | +1,756,217+16.9% |
| Paradigm Biocapital Advisors LPadded · filed 14 Aug 2026 | 8,670,576$108.5M | +650,000+8.1% |
| Jupiter Topco LLCnew · filed 14 Aug 2026 | 7,094,413$88.8M | +7,094,413 |
| Bain Capital Life Sciences Investors, LLCreduced · filed 14 Aug 2026 | 7,085,249$88.6M | -387,989−5.2% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 6,714,691$84.0M | +1,062,556+18.8% |
| BVF INCunchanged · filed 14 Aug 2026 | 5,295,893$66.3M | 00.0% |
| Siren, L.L.C.added · filed 13 Aug 2026 | 4,856,949$60.8M | +100,000+2.1% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 4,316,058$54.0M | +378,227+9.6% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 3,341,217$41.8M | +257,700+8.4% |
| Logos Global Management LPunchanged · filed 14 Aug 2026 | 3,208,875$40.1M | 00.0% |
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.